Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-3475 versus platinum-based chemotherapy in first-line PD-L1 strong metastatic non-small cell lung cancer
2014-000323-25Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- May 2014
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pembrolizumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Merck & Co. Primary endpoint: Progression-free survival. Started May 2014; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2014-000323-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000323-25.